Retatrutide 10 mg
Educational guide for reconstituting a 10 mg Retatrutide research vial and mapping weekly doses to U-100 units. Research use only.
Vial size
Same research phases — calculator defaults and unit math match the selected vial strength.
Vial
10 mg
Your BAC water
2 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Once weekly (same weekday)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (10 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
Quick-select common research doses (includes 2.5 / 7.5 for dual-agonist ladders) or type any mg / mcg value.
Quick select (mg) — switch units or type any value
Suggested: 50-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
40 units
Volume
0.400 mL
Doses per vial
5
Syringes needed
1
Barrel
50-unit
Fits one syringe?
Yes
50-unit · 0.5 mL
Filled to 40 u
Fill one 50-unit U-100 syringe to about 40 units (0.400 mL).
Weekly research phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 5.00 mg/mL · 50.0 mcg/unit).
Standard titration
Research-community tables often start ~2 mg weekly and titrate toward ~4–8+ mg. Not an approved drug product; trial designs differ.
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Weeks 1–4 | 2 mg2,000 mcg | 40 u | 0.40 mLIntroductory research-community amount |
| Weeks 5–8 | 4 mg4,000 mcg | 80 u | 0.80 mLPrefer 100-unit syringe |
| Weeks 9–12 | 6 mg6,000 mcg | 120 u | 1.20 mLVolume >1.0 mL — split across two injection sites |
| Weeks 13+ | 8 mg8,000 mcg | 160 u | 1.60 mLCommon maintenance discussion range |
Advanced / higher-end
Faster escalation discussed in research communities — not a clinical recommendation
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Aggressive · Weeks 1–4 | 4 mg4,000 mcg | 80 u | 0.80 mLPrefer 100-unit syringe |
| Aggressive · Weeks 5–8 | 8 mg8,000 mcg | 160 u | 1.60 mLVolume >1.0 mL — split across two injection sites |
| Aggressive · Weeks 9–12 | 10 mg10,000 mcg | 200 u | 2.00 mLUpper educational range — check syringe capacity |
Supplies planner
Using the guide’s phase ladder (2 mg → 4 mg → 6 mg weekly (phase ladder)) over a 12-week schedule. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
12-week schedule
Retatrutide 10 mg vials
5 vials
~48 mg mg total peptide over this 12-week schedule at 2 mg → 4 mg → 6 mg weekly (phase ladder). Each vial holds 10 mg.
Bacteriostatic water
4 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 5 vials = 10.0 mL total. Buy as 4× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
16+ syringes
Some doses need more than one 100-unit syringe at your concentration — plan extras and split draws when the math exceeds the barrel.
Alcohol swabs & sharps
~42 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 10 mg vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. “5.0 mg/mL”).
- Refrigerate at 2–8 °C (35–46 °F), protected from light.
Storage
Lyophilized
Keep dry powder cold and dark (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw. Prefer using within ~28 days with sterile technique.
- ·Write recon date and BAC volume on the label.
- ·Protect from light.
- ·Discard if cloudy, particulates, or odd odor appear.
Protocol notes
- ·Weekly subcutaneous research framing — not daily.
- ·Titrate slowly; GI-class effects are commonly discussed for multi-agonist incretin research peptides.
- ·Rotate injection sites.
- ·Research use only. Not medical advice.
Research context & considerations
Retatrutide is an investigational triple agonist (GLP-1 / GIP / glucagon pathways) studied for obesity and metabolic outcomes. Research-market vials are not the same as clinical trial drug product and are not FDA-approved for consumer use.
- ·GI effects (nausea, etc.) are commonly discussed for the class.
- ·Not for pregnancy, breastfeeding, or pediatric use.
- ·Personal/family medullary thyroid carcinoma and MEN2 are classic GLP-1-class caution contexts in approved-drug labels — relevant as research caution framing.
- ·Not a substitute for licensed medical care.
Catalog match
Retatrutide (RT10)
10mg x 10 vials · from $55